Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.47 |
| ▸ | CPB1 | P15086 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.41 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364250 | 0.93 | KDM5A (0.43) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL2327699 | 0.86 | CPB2 (0.47) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL17396261 | 0.85 | CPB1 (0.45) | CPB2CPB1KDM5AMEN1KMT2A | |
| SCHEMBL2331925 | 0.84 | CPB2 (0.45) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL20497248 | 0.84 | PIM1 (0.45) | KMT2A | |
| SCHEMBL20497250 | 0.84 | PIM1 (0.45) | KMT2A | |
| SCHEMBL28070514 | 0.83 | CPB2 (0.44) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL20497273 | 0.82 | CPB2 (0.38) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL12985681 | 0.81 | CDK5 (0.48) | CPB2CPB1CDK5CDK5R1KDM5A | |
| SCHEMBL20497264 | 0.80 | KDM2B (0.52) | CPB1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| WO-2021016333-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | CPB2 3736/4885CPB1 3835/4885CDK5 793/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CPB2 4325/4885CPB1 3845/4885CDK5 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.